[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604345":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":25,"responsibleParty":43,"collaborators":10,"id":45,"slug":10,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":46,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":10,"studyType":58,"phases":10,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":28,"whyStopped":10,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Epiliquid Holding, Inc","INDUSTRY",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"HCC-cases",null,"Patients with histologically confirmed hepatocellular carcinoma",{"label":13,"type":10,"description":14,"interventionNames":10},"Controls","Patients with liver cirrhosis without evidence of HCC",[16,21],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"Dr. Victoria Bocanegra, MD, PhD.","CONTACT","+5492616603254","victoria.bocanegra@epiliquid.com",{"name":22,"role":18,"phone":23,"phoneExt":10,"email":24},"Dr. Emanuel Campoy, PhD.","+5492615997899","emanuel.campoy@epiliquid.com",[26],{"facility":27,"status":28,"city":29,"state":10,"zip":30,"country":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"Epiliquid","RECRUITING","Mendoza","5500","Argentina",{"type":33,"coordinates":34},"Point",[35,36],-68.84582,-32.88946,{"lat":36,"lon":35},[39],{"name":40,"role":18,"phone":41,"phoneExt":10,"email":42},"Alejandro Ledesma, M.Sc","+549 1140681732","alejandro.ledesma@epiliquid.com",{"type":44,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100604345",false,"NCT07148310","Hepatocellular Carcinoma Identification Using Delta-HLD","Proof-of-Concept Case-Control Study for Hepatocellular Carcinoma Identification Using Delta-HLD Technology (HIDE)","HIDE","Inclusion Criteria:\n\n* Histologically confirmed HCC (cases) or clinically confirmed liver cirrhosis without HCC (controls)\n* Willing and able to provide informed consent\n* Available paired plasma and liver tissue sample\n\nExclusion Criteria:\n\n* Other active cancers\n* Prior liver transplantation\n* Known hereditary cancer syndromes\n* Recent chemotherapy or antiviral treatment (\\\u003C3 months)","ALL","18 Years","75 Years",{"count":56,"type":57},200,"ESTIMATED","OBSERVATIONAL","HIDE (Hepatocellular Carcinoma Identification via Delta-HLD) is a proof-of-concept case-control study designed to evaluate the performance of delta-HLD, Epiliquid's proprietary liquid biopsy technology, in detecting hepatocellular carcinoma (HCC). The study includes both plasma and tissue samples to assess biomarker concordance and evaluate diagnostic sensitivity and specificity using tumor-specific methylation markers detected by PCR.",[61],"Hepato Cellular Carcinoma (HCC)",[63,64,65,66,67,68,69],"Hepatocellular carcinoma","Epigenetics","Liquid Biopsy","cfDNA","Biomarker","Methylation","PCR","2025-09-08",{"date":72,"type":73},"2025-09-09","ACTUAL",{"date":75,"type":73},"2023-05-18",{"date":77,"type":57},"2026-12",{"name":5,"class":6},1]